Back to Innovators

Shine-On Biomedical is deploying and engineering secreted extracellular vesicles (EV) and exosomes, taking its natural transmission advantages to develop an entirely novel class of bio-therapeutics. With a comprehensive intellectual property portfolio creation including proprietary manufacturing, purification, and preservation methods, as well as a clinical translation platform establishment, Shine-On Biomedical’s EV novel therapeutics, Troy-Exos, are engineered exosomes with a safe and potent modality for precision delivery of advanced payloads. Troy-Exos owned a patented endogenous immune checkpoint antibody and designed a novel genetic engineering modification method to fuse on the EV's membrane proteins. Furthermore, they are loaded with small molecules and nucleic acid drugs with high efficiency. This nano-level immune checkpoint nanobody acting as Troy-Exos’ target is highly-expressed outside the double-layer phospholipid layer of exosomes, which increases the specificity of exosomes to attack tumors instead of normal tissue cells. In addition, Troy-Exos with immune checkpoint nanobodies can also prohibit the inhibitory effect of immune cells caused by immune checkpoint antigens after binding to tumor cells, thus increasing the killing of tumor cells by T cells.